2022 journal article

Nanoparticles functionalized with stem cell secretome and CXCR4-overexpressing endothelial membrane for targeted osteoporosis therapy

JOURNAL OF NANOBIOTECHNOLOGY, 20(1).

By: C. Zhang n, W. Zhang*, D. Zhu n, Z. Li n, Z. Wang n, J. Li n, X. Mei n, W. Xu*, K. Cheng n, B. Zhong*

co-author countries: China 🇨🇳 United States of America 🇺🇸
author keywords: Osteoporosis; CXCR4; Secretome; Mesenchymal stem cells; Bone targeting; Nanoparticles
MeSH headings : Animals; Cell Membrane / chemistry; Cell Membrane / metabolism; Disease Models, Animal; Endothelial Cells / chemistry; Endothelial Cells / metabolism; Mesenchymal Stem Cells / chemistry; Mesenchymal Stem Cells / metabolism; Nanoparticle Drug Delivery System; Nanoparticles; Osteoporosis / metabolism; Rats; Receptors, CXCR4 / metabolism; Secretome / metabolism
Source: Web Of Science
Added: January 24, 2022

Abstract Background Osteoporosis is a chronic condition affecting patients’ morbidity and mortality and represents a big socioeconomic burden. Because stem cells can proliferate and differentiate into bone-forming cells, stem cell therapy for osteoporosis has been widely studied. However, cells as a live drug face multiple challenges because of their instability during preservation and transportation. In addition, cell therapy has potential adverse effects such as embolism, tumorigenicity, and immunogenicity. Results Herein, we sought to use cell-mimicking and targeted therapeutic nanoparticles to replace stem cells. We fabricated nanoparticles (NPs) using polylactic-co-glycolic acid (PLGA) loaded with the secretome (Sec) from mesenchymal stem cells (MSCs) to form MSC-Sec NPs. Furthermore, we cloaked the nanoparticles with the membranes from C–X–C chemokine receptor type 4 (CXCR4)-expressing human microvascular endothelial cells (HMECs) to generate MSC-Sec/CXCR4 NP. CXCR4 can target the nanoparticles to the bone microenvironment under osteoporosis based on the CXCR4/SDF-1 axis. Conclusions In a rat model of osteoporosis, MSC-Sec/CXCR4 NP were found to accumulate in bone, and such treatment inhibited osteoclast differentiation while promoting osteogenic proliferation. In addition, our results showed that MSC-Sec/CXCR4 NPs reduce OVX-induced bone mass attenuation in OVX rats. Graphical Abstract